



## King's Research Portal

DOI:

[10.1080/21678421.2016.1267768](https://doi.org/10.1080/21678421.2016.1267768)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Strong, M. J., Abrahams, S., Goldstein, L. H., Woolley, S., Mclaughlin, P., Snowden, J., Mioshi, E., Roberts-South, A., Benatar, M., HortobáGyi, T., Rosenfeld, J., Silani, V., Ince, P. G., & Turner, M. R. (2017). Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotrophic lateral sclerosis & frontotemporal degeneration*, 1-22. <https://doi.org/10.1080/21678421.2016.1267768>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

ACCEPTED FOR PUBLICATION IN AMYOTROPHIC LATERAL SCLEROSIS AND  
FRONTOTEMPORAL DEGENERATION

Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised  
diagnostic criteria.

Michael J. Strong<sup>1</sup>, Sharon Abrahams<sup>2</sup>, Laura H. Goldstein<sup>3</sup>, Susan Woolley<sup>4</sup>, Paula  
McLaughlin<sup>5</sup>, Julie Snowden<sup>6</sup>, Eneida Mioshi<sup>7</sup>, Angie Roberts-South<sup>8</sup>, Michael Benatar<sup>9</sup>, Tibor  
Hortobágyi<sup>10</sup>, Jeffrey Rosenfeld<sup>11</sup>, Vincenzo Silani<sup>12</sup>, Paul G Ince<sup>13</sup>, Martin R. Turner<sup>14</sup>

1. Department of Clinical Neurological Sciences, Schulich School of Medicine & Dentistry,  
London, Ontario, Canada
2. Department of Psychology, School of Philosophy, Psychology & Language Sciences, Euan  
MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh,  
Edinburgh, UK
3. King's College London, Department of Psychology, Institute of Psychiatry, Psychology and  
Neuroscience, De Crespigny Park, London, UK
4. Forbes Norris MDA/ALS Research Centre, California Pacific Medical Centre, San  
Francisco, California, USA
5. Western University, Schulich School of Medicine & Dentistry, London, Ontario, Canada
6. Greater Manchester Neuroscience Centre, Salford Royal NHS Trust and University of  
Manchester, Manchester, UK
7. Faculty of Medicine and Health Sciences, University of East Anglia, Norwich UK
8. Northwestern University, Roxelyn and Richard Pepper Department of Communication  
Sciences and Disorders, Evanston, Illinois, USA
9. Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida,  
USA
10. Department of Neuropathology, Institute of Pathology, University of Debrecen, Debrecen,  
Hungary

11. Department of Neurology, Loma Linda University School of Medicine, Loma Linda, California, USA
12. Department of Neurology and Laboratory Neuroscience - IRCCS Istituto Auxologico Italiano, Department of Pathophysiology and Transplantation, 'Dino Ferrari' Centre, Università degli Studi di Milano, Milan, Italy
13. Sheffield Institute for Translational Neuroscience, Department of Neuroscience, The University of Sheffield, Sheffield, UK
14. Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

Address correspondence to: Michael J Strong, MD, Room C7-120, UH-LHSC, 339 Windermere Road, London, Ontario, N6A 5A5

Phone: 519-663-3874

Fax: 519 -663-3609

Email: [Michael.Strong@Schulich.uwo.ca](mailto:Michael.Strong@Schulich.uwo.ca)

Key words: Amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), neuropsychology, cognition, behaviour, genetics

**Abstract**

This article presents the revised consensus criteria for the diagnosis of frontotemporal dysfunction in amyotrophic lateral sclerosis (ALS) based on an international research workshop on frontotemporal dementia (FTD) and ALS held in London, Canada in June 2015. Since the publication of the Strong criteria, there have been considerable advances in the understanding of the neuropsychological profile of patients with ALS. Not only is the breadth and depth of neuropsychological findings broader than previously recognized - including deficits in social cognition and language – but mixed deficits may also occur. Evidence now shows that the neuropsychological deficits in ALS are extremely heterogeneous, affecting over 50% of persons with ALS. When present, these deficits significantly and adversely impact patient survival. It is the recognition of this clinical heterogeneity in association with neuroimaging, genetic and neuropathological advances that has led to the current re-conceptualization that neuropsychological deficits in ALS fall along a spectrum. These revised consensus criteria expand upon those of 2009 and embrace the concept of the frontotemporal spectrum disorder of ALS (ALS-FTSD).

## Introduction

While the core feature of amyotrophic lateral sclerosis (ALS) is a relentless loss of motor function leading to paralysis and ultimately death, the awareness that it can be associated with one or more features of frontotemporal dysfunction has gained increasing acceptance (1). This in part can be traced to the development of international criteria for the diagnosis of frontotemporal dysfunction in ALS in 2009 (Strong criteria) (2;3). These criteria, which incorporated clinical, electrophysiological, neuropsychological, genetic and neuropathological characteristics, recognized that ALS could exist as a pure motor syndrome but that it can co-exist with a frontotemporal dementia (ALS-FTD) as defined by the Neary or Hodges criteria (4;5). The criteria further recognized that both behavior and/or cognitive features, not sufficient to meet criteria for the diagnosis of dementia but sufficient to be detected and/or give rise to impairment, could exist (termed ALS behavioral impairment [ALSbi] and ALS cognitive impairment [ALSci], respectively). The criteria also acknowledged that a small population of patients could develop dementia not typical of FTD (ALS-Dementia).

Since the introduction of the Strong criteria, our understanding of the breadth and impact of frontotemporal dysfunction has grown considerably. With this has come the realization that the Strong criteria do not adequately recognize impairments in social cognition, language or memory, or the presence of neuropsychiatric symptoms and that these deficits are manifestations of the spectrum of deficits resulting from frontotemporal dysfunction. It is for this reason that we believe that the term frontotemporal spectrum disorder (ALS-FTSD) is most appropriate to characterize the breadth and severity of frontotemporal dysfunction that can be encountered in association with ALS. Moreover, the Strong criteria were not readily adapted to languages other than English and were insufficiently operationalized for easy use in everyday clinical practice or in clinical trials. Equally important, there have been significant advances in the genetics of ALS which have provided novel insights into the pathobiology of ALS-FTSD. Given this, a consensus conference was convened in the summer of 2015 to revisit the 2009 Strong criteria. [A consensus development panel approach was utilized which consisted of a group of content experts \(manuscript authors\) who identified key topic areas of relevance to developing these revised international guidelines. The expert panel then identified key international content experts who attended and/or presented at the international consensus conference in the summer](#)

of 2015 (attendees listed in the acknowledgement section). At the end of day 3 of the consensus conference, a round table discussion was held in which all attendees provided input into the key parameters of the revised criteria. Members of the consensus panel formulated the revised criteria, following which the criteria were provided to the conference attendees for commentary and/or revisions.

To that end, this article presents the revised Strong criteria. In doing so, we have addressed several key issues, including the recognition that any criteria must be sufficiently broad to suffice for research purposes whilst at the same time be nimble enough to be of utility clinically. As such, beyond expanding the nature of neuropsychological and neuropsychiatric deficits that characterize ALS-FTSD, a key advance in this revision is the inclusion of three levels of complexity or depth of assessment: criteria which can be applied in everyday clinical use (Level I), those which can be utilized for prognostic stratification in clinical trials (Level II), and those which are considered as research intensive with the goal of better defining the nature and extent of FTSD in ALS (Level III) (Figure 1). The criteria are intentionally hierarchical. Level I incorporates tools that can be easily applied at the bedside and are of low statistical complexity, require the least amount of effort to implement, rely upon well-validated tools that have already been applied in the ALS population, and while not requiring neuropsychological support for implementation, would benefit from neuropsychological support for interpretation. Level III are the most advanced criteria and contain the core elements of the Level I testing but are of high statistical complexity, require a maximum amount of time and effort to complete, include research tools not yet validated in a broader ALS population, and would be considered research grade. Level II criteria are anticipated to be applicable to clinical trials where a moderate amount of effort could be expended. Level II criteria also would consist of a minimum dataset for inclusion in case publications. In contrast to Level I, Level II criteria require the engagement of either neuropsychologists or speech-language pathologists to evaluate the testing paradigms, to oversee or manage test administration and to interpret results.

Participants at the consensus conference also agreed that the core features of the diagnostic algorithm, and most specifically the use of the diagnostic axis model, should remain whilst recognizing that specific components would need either modification or expansion. Given this, the revised criteria continue to use the three primary ‘diagnostic axes’, including: Axis I –

defining the motor neuron disease variant; Axis II – defining the cognitive and behavioural dysfunction; and, Axis III – additional non-motor disease manifestations. It was felt that the use of Axis IV which previously was included in order to define the presence of disease modifiers, did not contribute to the characterization of the FTSD of ALS and thus it has been omitted in the revised criteria presented herein.

**Axis I. *Defining the motor neuron disease variant***

The phenotypic variability within ALS is significant and includes variability in age of onset, site of onset, the degree of upper versus lower motor involvement, the rate of disease progression and survival. Until such time as the basis for this heterogeneity is elucidated, it is helpful to recognize distinct clinical syndromes which may be characterized by the predominance of upper motor neuron degeneration (e.g. primary lateral sclerosis [PLS]), lower motor neuron neurodegeneration (e.g. progressive muscular atrophy [PMA]), or a combination of both UMN and LMN degeneration which typifies the most frequent phenotype, namely ALS; by the neuroanatomical region primarily affected (e.g. progressive bulbar palsy [PBP]); or by the absence (e.g. monomelic amyotrophy) or presence of left-right symmetry (e.g. brachial amyotrophic diplegia, also known as flail arm, or leg amyotrophic diplegia).

**Axis I diagnostic criteria.** Since the publication of the original Strong criteria, there has been considerable debate with respect to the minimal criteria necessary to diagnose ALS, particularly with respect to the presence or absence of active denervation as diagnostic of LMN dysfunction. In the original Strong criteria, it was recommended that the El Escorial criteria (revised) be used for the diagnosis of ALS (6-8). In doing so, a multimodality approach toward identification of both UMN and LMN dysfunction using both clinical and electrodiagnostic studies was recommended, along with incorporation of genetic studies as appropriate. Neuroimaging studies were felt to be contributory when structural pathology was considered a diagnostic possibility but were otherwise relegated to being a research tool. The criteria further required the absence of any disease process that might account for the findings. In this context, the diagnosis of ALS required the presence of multi-segmental LMN degeneration by either clinical or

electrophysiological criteria combined with evidence of UMN dysfunction, with progression. Progressive upper or lower motor neuron dysfunction in a single segment, even if isolated, was considered sufficient for the diagnosis in the presence of a mutation in a known ALS-causative gene.

There has since been considerable debate about the genesis of the delay in diagnosing ALS and whether such delays may in fact hamper not only enrollment in therapeutic trials but the ability to impact on the earliest stages of the disease process. This has led to the introduction of alternative diagnostic algorithms, the intent of which are to include greater numbers of patients in clinical studies or trials who may in fact have the potential of developing ALS whilst not yet fully manifesting the complete syndrome. The Awaji criteria, which emerged from a consensus conference held in 2006, proposed two fundamental changes to the revised El Escorial (9). The first proposed change was to use both electromyography and clinical data simultaneously to determine the presence of LMN dysfunction. For example, atrophy in an ulnar innervated C8 muscle along with evidence of LMN pathology in the deltoid muscle, would be sufficient to declare the limb/region affected. The second proposed change was to consider fasciculation potentials as evidence of ongoing denervation, equivalent in importance to fibrillation potentials. While controversy has arisen over the notion that fasciculations represent ongoing denervation, there is greater agreement that unstable and complex fasciculations should be accorded greater significance. The Awaji criteria have been shown to have a higher sensitivity than the El Escorial criteria (revised) while maintaining the same specificity, with the diagnostic benefits being most apparent in the bulbar onset and limb-onset patients (10-12). This increased sensitivity, however, is gained in large part by the combination of two El Escorial criteria (probable and laboratory supported probable) into a single category. The introduction of a “possible” diagnostic category to the Awaji criteria was of particular benefit in enhancing the early diagnosis of ALS and more specifically in the limb-onset subgroup (13).

More recently, the El Escorial criteria have been revisited in an effort to accommodate a postulated broader ALS phenotype (14). The revised iteration of the criteria proposed that the diagnosis of ALS would require, at minimum, progressive UMN and LMN deficits in at least one limb or region (previous possible ALS) or lower motor neuron deficits as defined by clinical examination (one region) and/or by EMG in two body regions (defined as bulbar, cervical,



thoracic, lumbosacral). The EMG findings needed to include of neurogenic potentials and fibrillation potentials and/or sharp waves. In this scheme, restricted phenotypes of ALS would now be considered as including progressive bulbar palsy, flail arm and flail leg syndrome, progressive muscular atrophy and primary lateral sclerosis. In the context of the flail arm and flail leg syndromes, as well as progressive muscular atrophy, the diagnosis of ALS could be rendered in the absence of evidence of UMN dysfunction. It was noted however that the modifications of the El Escorial criteria as proposed by Ludolph and colleagues were as yet to be validated in longitudinal studies, and in particular the inclusion of pure LMN syndromes, as being equivalent to a diagnosis of ALS.

The role of biomarkers in the diagnosis and monitoring of progression in ALS continues to evolve, although to date, no markers specific to the presence of frontotemporal dysfunction have been validated. Thus while there is evidence to suggest that a number of biomarkers within either cerebrospinal fluid or blood may prove to be of value in the diagnostic work-up of ALS patients with or without frontotemporal dysfunction, including high molecular weight neurofilament, phospho-tau (including measures of total tau), TDP-43, APOE ε2 and beta-amyloid are not yet ready to be included in Level I diagnostic workup (15-21). Further, while it is increasingly likely that proteomic profiling of CSF will enhance the sensitivity and specificity of biomarker utilization in the diagnosis when used either independently or within a broader array of investigations including MR imaging (22;23), such testing should remain within the Level III workup although a restricted number (e.g., pNFH, phospho-tau, TDP-43, APOE ε2) could be considered in Level II.

Deleted:

**Axis I genetic diagnosis.** Since the publication of the original consensus criteria, significant advances have been made in our understanding of the genetic underpinnings of ALS – there are now over 17 Mendelian variants known to be associated with ALS which are considered causative (Table 1). In addition to these genes, an ever-expanding list of disease-associated or disease-modifying genes are being discovered (Supplementary Table 1). Although these discoveries are helping to advance our understanding of ALS, they also add substantial complexity in the clinical realm. While genetic characterization of patients with ALS and ALS-FTSD is encouraged, it is critical to remember that the identification of a pathogenic variant in

an ALS-causing gene does not imply the presence of disease. Moreover, while the term ‘familial’ remains useful in describing the presence of a family history (i.e. at least two affected biological relatives) and as a surrogate for the likelihood of identifying a genetic cause of disease, it is important to remember that all genes implicated in familial forms of ALS also have been found to harbor mutations in a small subset of patients with apparently sporadic ALS. Moreover, by virtue of factors such as recessive inheritance, compound heterozygosity, *de novo* mutations, misdiagnosis, small sibship size, reduced penetrance, lack of family information, including paternity, etc., a family history may frequently be lacking in genetic forms of disease. The term ‘familial’ therefore should not be used interchangeably with ‘genetic’ (24). Conversely, given a lifetime risk of ALS, which approximates 1:350 for men and 1:400 for women, coincidental familial clustering is a realistic consideration amongst pedigrees with only two affected individuals which might otherwise be considered to be clinical examples of Mendelian inheritance (24).

Amongst ALS-disease causing genes, there are several that bear specific mention because their presence is disproportionately associated with frontotemporal dysfunction in ALS, sufficient to warrant genetic testing among those individuals with frontotemporal dysfunction regardless of the presence or absence of a family history. The prototypic gene amongst these is represented by the pathological hexanucleotide repeat (GGGGCC) expansions of *C9orf72* which is the most common genetic modification affecting fALS (60 – 70%) as well as those afflicted with familial FTD (approximately 18% of cases). The presence of cognitive impairment in patients carrying a *C9orf72* expansion is several fold greater than those without (40 – 50% vs 8 – 9%, respectively) (25). In rare instances in which ALS patients present with psychosis and marked lack of insight, there is also a higher likelihood of harbouring the pathological *C9orf72* expansion (26).

**Axis I recommendation.** The classification of the frontotemporal dysfunction in ALS should be hierarchical and begin with a description of the motor neuron disorder/syndrome. While consensus has not yet been achieved with respect to the use of clinical syndromic terms, we perceive value in the use of terms such as progressive muscular atrophy, upper motor neuron predominant ALS and progressive bulbar palsy, for example, and recognize that the clinical

syndrome may evolve over time. Such terminology is appropriately used in the clinic (Level I), in clinical trials (Level II) and as part of the broader research endeavor (Level III). Quite distinct from this syndromic nomenclature, however, is the use of diagnostic criteria such as the revised El Escorial and Awaji criteria for clinical trials (Level II) and research purposes (Level III). It is recommended that patients diagnosed with ALS should fulfill either the El Escorial criteria (revised) or the Awaji criteria (revised).

Genetic testing is recommended when a family history is present (by which we mean that at least one other biological relative has been diagnosed with ALS or FTD), as the El Escorial criteria require only progressive upper or lower motor neuron dysfunction in the presence of a mutation in a gene known to cause ALS. We recommend that the term ‘genetic ALS’ be used instead of ‘familial ALS’, especially when a genetic cause of disease is identified despite the absence of a family history. Appropriate genetic counseling should always be provided. For clinical trials (level II) and for research purposes (level III), a full genetic analysis (either a panel of genes established to cause ALS (Table 1), or whole exome/genome sequencing) is encouraged, and genetic counseling provided whenever genetic test results will be shared with the patient.

### ***Axis II. Defining the neuropsychological deficits.***

The Strong criteria recognised the potential presence of FTD in ALS and for those patients not reaching threshold for a full FTD diagnosis, also provided a means of classifying the presence of cognitive or behavioural involvement: ALS<sub>ci</sub> and ALS<sub>bi</sub>, respectively. Since the publication of the consensus criteria in 2009, however, developments in the field have necessitated the revision of these definitions. Firstly, increasing evidence has accrued as to the heterogeneity of cognitive impairment in ALS. Thus while previous emphasis had been placed on executive dysfunction, there is now evidence that language dysfunction may be as, if not more, common and can occur in patients without executive dysfunction (27;28). Deficits in social cognition also have been highlighted, although it is not entirely clear whether social cognition deficits are completely independent of executive dysfunction in ALS (29-36). In addition, while the original ALS<sub>ci</sub> and ALS<sub>bi</sub> classifications have been borne out by cluster analysis, it has been suggested that other cognitively-impaired patients cannot be classified according to the original criteria (36). There is

also some controversy (to be considered below) about the role of memory dysfunction in the classification of cognitive impairment in people with ALS. Secondly, revised consensus criteria for the diagnosis of behavioural variant FTD (bvFTD) highlight the need for revising the current consensus criteria (37).

Our aim, therefore, is to revise the previous classifications of cognitive and behavioural involvement in ALS to take into account the extended evidence base of potential deficits that may need to be considered in arriving at a classification of impairment and to account for the increased knowledge and heterogeneity of impairment profiles. Firstly, we examine the developments below in specific cognitive domains that have given rise to this need for revision. Then we consider revisions to the classification of behavioural and neuropsychiatric symptoms and provide recommendations regarding testing paradigms (Supplemental Table 2).

#### NEUROPSYCHOLOGICAL DOMAINS

##### a) Executive dysfunction and Social Cognition

Executive dysfunction is characteristic of the profile of cognitive deficits in ALS (38), a finding that has been confirmed through population based studies (39) and meta-analyses (40). The signature executive functions deficit is demonstrated through assessment of verbal fluency (41-44). This is a commonly used clinical instrument, involving the generation of lists of words beginning with a specified letter (letter fluency) or semantic category (e.g. animal fluency); the former being the more widely recognised marker of impairment in ALS. Letter fluency involves the interaction of a number of cognitive processes, specifically executive processes of initiation, strategy formation, set-shifting, sustained attention and inhibition, but in addition language functions involved in word retrieval. It has been shown that poor letter fluency in ALS is related to executive dysfunction (41). Deficits on letter fluency tasks occur early in the course of the disease (45), correlate with ocular movement abnormalities (46), and are more prominent in but not restricted to patients with pseudobulbar palsy (42). Based on limited published literature, impaired verbal fluency does not appear to be a feature of SOD1 ALS (47).

Verbal fluency deficits in ALS also have been shown to be a marker of frontal lobe dysfunction, in particular the dorsolateral prefrontal cortex and inferior frontal gyrus, as demonstrated with functional and structural neuroimaging (48-51). Performance in verbal

fluency can be affected by motor disability with difficulties in writing or in speaking which magnify deficits. This has necessitated the development of the Verbal Fluency Index that controls for physical motor impairments by incorporating a timed condition in which the person either reads or copies previously generated words and from which an estimate of the average time taken to think of each word is calculated. Using the Verbal Fluency Index, deficits have been repeatedly demonstrated which are independent of motor disability (41).

Executive dysfunction in ALS has been revealed across a range of tests including readily available clinical measures and experimental procedures. Deficits have been reliably shown on standard assessments measuring attention monitoring and switching, rule deduction, and cognitive flexibility, such as the Trail Making Test or the Wisconsin Card Sorting Test (52;53). A recent meta-analysis of studies using the latter revealed that patients with ALS made more errors (continuing to choose the previously correct rule) and took longer to learn new rules (54). Similar impairments have been shown on other card sorting concept formation tasks such as from the Delis-Kaplan Executive Function System Sorting Test (34;55). Furthermore, deficits have been revealed on tests highly reliant on manipulating concepts in working memory such as reverse digit span or the N-Back task and most recently on tests of divided attention in which two tasks are undertaken concurrently, such as visual processing speed task and digit recall (51).

Performance on standard neuropsychological tests of executive function are mostly mediated by functions of the dorsolateral prefrontal cortex, but studies have also revealed deficits using experimental measures more dependent on orbitomedial prefrontal functions. ALS patients have shown abnormal risk taking on the Iowa Gambling Task (29). Deficits have been shown using two more ecologically valid measures of executive functions where patients demonstrate difficulties in reasoning, coordinating rules and mental heuristics: the Medication Scheduling Task (56) and the Holiday Apartment Task (57).

Social cognition has recently become a focus of investigation in ALS, having been a notable feature of the FTD profile for some time. A recently updated meta-analysis noted the new addition of social cognition deficits as integral to the cognitive profile in ALS (40). Nevertheless there remains some debate as to the source of the deficits in social cognition with some studies showing an independence of executive dysfunction and others not (34;57). Patients with ALS show deficits across a range of social cognitive processes including altered emotional processing and reduced capacity to recognize emotional (particularly negative) facial expressions

although this is more likely in those with ALS-FTD (29;58-60). ALS patients also have difficulty on tests specific to Theory of Mind, in which the thoughts or beliefs of another are inferred. One third of patients have been shown to be impaired at detecting a faux pas (57) and such difficulties have been related to specific problems with understanding social situations (30). A fundamental process in social cognition is the interpretation of the direction of eye gaze as assessed through the Judgement of Preference Task (29). The finding of a deficit on this task was extended to reveal impaired affective and to a lesser extent cognitive Theory of Mind (35).

In patients meeting criteria for ALS-FTD, executive/social cognition deficits are a virtually ubiquitous feature and cover the range of difficulties described above.

b) Language dysfunction

The last two decades have seen a rising interest in defining the prevalence and the nature of the language impairment in ALS (27;39;61-64). The extent to which impairments in word retrieval, sentence processing, spoken language, and pragmatic language are 'pure' language deficits versus downstream manifestations of other disrupted cognitive domains (e.g., executive function) continues to be debated. Not all patients with ALS present with obvious language impairments (65). Moreover, language deficits in ALS can be challenging to disentangle from motor speech deficits and also from ALS-FTD, which can present similarly to semantic and non-fluent variants of primary progressive aphasia. Notwithstanding these diagnostic challenges, an estimated 35-40% of individuals with ALS but no dementia may demonstrate language impairments (27). These language impairments are dissociable from motor and executive function impairments (28;62;66-69), raising the possibility that impairments in language may both contribute to the profile of ALS and also occur as part of a mixed cognitive profile that includes executive function impairments or social cognition impairments (27;36).

In ALS, word retrieval for nouns and object knowledge are often reported as mildly impaired compared with controls (28;49;62;70;71). In contrast to nouns, verb naming and action verb processing deficits are a more consistent finding in ALS (27;28;62;69;71-73). Verb deficits in ALS are often associated with atrophy in the dorsolateral prefrontal cortex and motor cortices (69;71;72). As such, they may be an important marker of cognitive impairment in ALS. While the theoretical underpinning of the object-action (i.e., noun-action verb) dissociation observed in ALS remains unclear (73), these findings suggest that the assessment of word retrieval

impairments may benefit from including tests that measure the retrieval and comprehension of both nouns and action verbs.

Sentence processing difficulties also have emerged as a prominent feature in the language profile of ALS (27;28;72;74;75). Recent work suggests that syntax and sentence processing deficits in ALS likely exist on a spectrum with modest impairments emerging in ALS that progress in severity for patients with ALS-FTD (75). While more research is needed, deficits in syntax processing have been dissociated from both executive function and motor speech impairments (28), suggesting that syntax processing impairments may contribute uniquely to the language profile of ALS.

There is emerging evidence that, in addition to sentence processing deficits, individuals with ALS also produce sentences with a greater number of grammar and morphology errors compared to healthy adults (28;62;66). Grammatical errors reported from studies of spoken language in ALS include incomplete utterances (28;66;68), missing determiners (66), and verb phrase errors (66). Productivity deficits also characterize the spoken language of individuals with ALS including reduced utterance length and lower total word output, features that are likely related to the motor speech and respiratory challenges in ALS (28;67;68). Beyond grammar and productivity impairments, other linguistic and pragmatic aspects of spoken language are affected in ALS including informativeness (e.g., fewer content or information words in proportion to the total words produced) (68;76); semantic and verbal paraphasias (28;68); poor narrative coherence and cohesion (66); and impaired topic management (76). While it remains an evolving area of research, investigators have reported impaired pragmatic language in ALS including figurative and non-literal language processing, findings that are often attributed to frontal lobe dysfunction (76).

Collectively, the research over the last decade underscores the importance of considering language impairments in the profile of ALS. Although analysis of spoken language tasks may be more challenging for typical clinical environments, due to their more labour intensive analyses, clinicians and researchers can glean much about the profile of language impairments in ALS using a number of available standardized instruments (Supplemental Table 2).

The relationship between language impairment and ALS-FTD also is incompletely understood. Progressive non-fluent aphasia (PNFA) and semantic dementia (SD) are clinical forms of frontotemporal lobar degeneration incorporated within previous diagnostic criteria (5).

Both PNFA and SD have been reported in association with ALS (77-80). On the other hand, specific language problems, such as in syntactic comprehension, are reported to be common in patients meeting behavioural criteria for ALS-FTD (75). Criteria for ALS-FTD need to recognise that language problems play a contributory role.

c) Memory

Memory deficits in ALS have been studied extensively. However in the current recommendations, isolated memory impairment does not meet the criteria for a diagnosis of ALSci. The exclusion of memory dysfunction from the current criteria relates in part to the lack of consensus about the characterization of memory deficits in ALS. Study results are wide ranging and have identified impairments in encoding (81-83), immediate or delayed recall (39;78;81;83-85), recognition (86), or the involvement of a combination of memory processes. Other studies suggest intact recognition memory (39;83;87).

An updated meta-analysis in ALS showed a small effect size for delayed verbal memory as well as executive dysfunction, with larger effect sizes for other domains (fluency, language and social cognition) (40). Although delayed verbal memory recall was associated with a greater effect size than visual memory (40), visual memory deficits have been detected (78). Memory deficits are detected in ALS patients without dementia that correlate with grey matter hippocampal volumes (85) and memory scores may differ significantly from controls even in cognitively-normal ALS patients (78). ALS patients with baseline cognitive impairment demonstrate decline in verbal delayed recall when studied longitudinally (84).

Of importance for further understanding why isolated memory involvement should not be used to classify ALSci, memory impairment in ALS rarely occurs in isolation (4%), which is a comparable rate to that seen in controls (39). The association between executive dysfunction and memory impairment in ALS is asserted repeatedly (78;81-83;86;87). Variables such as selective attention and mental control explain substantial variance in memory scores. Interestingly, memory deficits are the least common co-morbidity in ALSci patients who present with executive dysfunction (39).

With respect to the broader implications of detecting memory impairment in people with ALS, a population based study detected Alzheimer's disease (AD) in 1.9% of ALS patients, compared to 13.8% of the sample who had FTD (39). In a study of 279 ALS patients (78), <2%



met diagnostic criteria for AD, a frequency lower than the national rate of AD in 4% of the US population of adults below age 64 (88). In the ALS study, similarities in cognitive performance across cognitive diagnostic subgroups suggested different levels of severity within the same progressive disease subsumed by executive dysfunction. The results did not support the presence of discrete subtypes (i.e. an amnesic subtype). Qualitative differences in memory distinguish ALS patients from patients with AD (83) and those with the AD prodrome of mild cognitive impairment-amnesic type (86).

Although isolated memory impairment does not qualify for the diagnosis of ALS<sub>ci</sub>, memory impairment may nonetheless be problematic for patients, particularly for those in the older age segment of its distribution. To better understand its nature, assessment of memory in ALS should also analyse domains of attention, language, and executive functioning and age-related changes in the speed of processing. Ideally, research studies investigating memory should analyse multiple variables such as encoding, storage, recall, processing speed, and recognition rather than summarizing a single memory composite score, which may obscure the understanding of the specific memory deficit (86). As with any clinical evaluation, memory assessment in ALS should consider alternative conditions that result in memory impairment and factors such as respiratory muscle weakness that may give rise to nocturnal hypoxaemia. Supplemental Table 2 provides a list of screening measures and comprehensive memory tests which can be used in the ALS population.

#### d) Behavioural changes and neuropsychiatric symptoms

Apathy is the most frequently identified behaviour symptom in ALS, detected in up to 70% of patients (89-95). There is not a clear link to specific ALS phenotypes; apathy being pervasive, and severe apathy being linked to poorer prognosis in ALS (96). ALS patients may present with other types of behaviour change including disinhibition, loss of sympathy/egocentric behaviour, perseverative and stereotyped behaviour and a change in dietary habits, although not as commonly as apathy (91;97;98).

When assessing behavioural change in ALS, it is important to consider potential confounds of respiratory insufficiency, physical disability and psychological reactions to the disease including mood. Reports from family members or friends are essential, especially in light

of the patient's lack of insight. Baseline/premorbid psychological and behavioural status must be determined in order to assess whether behavioural abnormalities are 1) new, 2) associated with the time of onset of ALS (recognizing as stated earlier that a proportion of FTD patients will develop either clinical or electrophysiological features consistent with either ALS or a motor neuron disease), and 3) disabling or causing clear impairment. Individuals assessing these patients also need to be knowledgeable about pseudobulbar affect, which may be misinterpreted by some as behavioural disinhibition, inappropriateness, or depression. In turn, the distinction between apathy and depression is of great relevance not only for the diagnosis of ALSbi, but also for the clinical management of depression (when present) and provision of family support.

It is important to acknowledge that these behavioural symptoms often co-exist with deficits in cognitive domains (see ALSbi; see table 3). In addition, ALSbi and ALSci can coexist with different levels of severity (99-101). In some patients the combination of behavioural and cognitive changes are sufficient to meet criteria for ALS-FTD.

Behavioural changes and neuropsychiatric symptoms have been merged into one category to align bvFTD current criteria with current research findings, as indicated in Supplemental Table 3.

## **Axis II recommendations**

Since the introduction of the Strong criteria, several reliable screening and assessment tools have been developed with which to describe the cognitive, behavioural and language profile of an ALS patient. These tools have been validated and are readily applied in the clinical setting, allowing for brief screening or testing that can be introduced efficiently into the clinic as an indicator of those ALS patients who may require more intensive study (Table 3). As such therefore, it is recommended that each patient receive a screening assessment as a component of a Level I evaluation and if impaired, that further testing is warranted.

*Screening and brief assessments.* Screening assessments are designed firstly to identify those individuals who have evidence of frontotemporal dysfunction, and secondly, to provide some degree of differentiation as to the type of dysfunction. Where ALS screening tests are

administered, ALSci is identified on the basis of the published cut-off scores. The advantage of using ALS screening tests such as the ECAS and ALS Cognitive Behavioral Screen (ALS-CBS) is that the identification of ALSci may otherwise be based on individual tests of variable levels of complexity, thereby contributing to the heterogeneity of identified samples. While both of these tools allow for the identification of ALSci, where further description of the extent of frontotemporal dysfunction is desirable, patients can then be assessed in greater detail using the tests proposed in Table 3. To that end, it is recommended that either the ECAS or the ALS-CBS be administered to all patients.

*The Edinburgh Cognitive and Behavioural ALS Screen (ECAS).* ECAS is a multidomain brief assessment developed for use within the clinic or home visits by non-neuropsychology health professionals (102;102). It assesses a range of functions typically affected in ALS (ALS-Specific: Fluency, Executive Functions, Language Functions) including newly recognised deficits in language and social cognition. In addition it assesses functions which are not typically affected in ALS but are common in disorders of older adults (ALS Non-specific: Memory, Visuospatial Functions). The ECAS also includes a separate semi-structured behaviour interview which should be undertaken with an informant/caregiver separately from the patient and is based on the five key behavioural domains for diagnosing FTD (see above) using the most recent diagnostic criteria (37) and can therefore be used to aid in the diagnosis of behavioural variant FTD.

The cognitive tests were specifically designed to allow for verbal and motor disability, incorporating the Verbal Fluency Index, and the whole assessment can be undertaken in either spoken or written format. The screen has been validated against extensive neuropsychological assessment and shows good sensitivity (85%) and specificity (85%) to cognitive impairment in ALS patients without dementia (103). In the English versions, abnormality cut off scores were 105/136 for ECAS-Total Score and 77/100 for ALS-Specific Score. A five-point borderline range (105-110) and (77-82) produced optimal values maximizing sensitivity without a significant reduction of specificity and is recommended particularly for highly educated patients. Additionally the ECAS has been validated in German (104), Italian (105) and Chinese (106) and shows convergent validity with other general cognitive screening tools, including the Frontal

Assessment Battery and the Montreal Cognitive Assessment. The ECAS has been translated into a number of other languages and adapted for a North American population.

*ALS Cognitive Behavioral Screen (ALS-CBS)*. The ALS-CBS (107) was developed as a quick, practical tool to aid in the identification of ALSci, ALSbi, and FTD in the clinical setting. It includes a cognitive section and a caregiver questionnaire. It has high concurrent validity with other ALS-specific measures (44) and has excellent accuracy (107). High inter-rater reliability and ease-of-use was demonstrated in a large, multicentre study (44). The ALS CBS has been translated into six languages and it has been validated in Portuguese (108) and Spanish (109). It is freely available and non-copyrighted, as is ECAS.

The ALS-CBS was developed to minimize motor or speech production involvement so patients can be tested during later stages of disease. Responses can be provided verbally or in writing and can be generated with speech output devices or communicated with eye movements or mouthing. It can be administered by any clinical staff member, and requires approximately 5 minutes to complete. The cognitive section measures attention, concentration, working memory, fluency and tracking. Only the verbal fluency item is timed. Certain cognitive items were chosen based on research which identified an association between errors made on specific items and the severity of cognitive impairment in ALS. Scoring combines correct responses minus deductions for errors, with a total possible score of 20. Lower scores reflect greater impairment. Optimal cut off scores were determined in the initial validation study (107). A cut-off of  $\leq 10$  for the cognitive section achieved 100% accuracy for identifying FTD in the study of ALS patients diagnosed with dementia based on a comprehensive neuropsychological battery. Scores at or below this cut-off raise strong suspicion of FTD and should prompt further assessment to confirm the diagnosis. A cut-off score of  $\leq 16$  suggests any cognitive impairment (either ALSci or ALS-FTD), and a score  $\geq 17$  is recommended to exclude cognitive impairment.

The behavioural section comprises a 15-item Likert scale questionnaire completed by an informant and assesses change since disease onset. Behavioural domains were selected to assess a variety of abnormalities known to occur in ALS and FTD, including alterations in empathy, personality, judgment, language, and insight. Total scores range from 0 to 45; lower scores indicate more pathology. For the behavioural section, a cutoff of  $\leq 32$  achieved 86% accuracy for

correctly classifying ALS patients with FTD and a score of  $\leq 36$  best detects any behavioural impairment (ALSbi or ALS-FTD). Scores above  $\geq 37$  are suggestive of normal behaviour.

**Domain-specific recommendations.**

**ALS with cognitive impairment (ALSci).** A diagnosis of ALSci depends on evidence of either executive dysfunction (including social cognition) or language dysfunction or a combination of the two.

Executive impairment is defined as:

1. Impaired verbal fluency (letter). Verbal fluency deficits must control for motor and/or speech impairments (41) to be valid  
OR
2. Impairment on two other non-overlapping measures (see below) of executive functions (which may include social cognition).

Language impairment is defined as:

1. Impairment on two non-overlapping tests (which could include pragmatic function).

As the investigator or clinician elects to move to a higher level of complexity or depth of assessment (ie., Level II and III; see Table 3), impairment on individual measures (not screening tests) is defined as a score falling at or below the 5th percentile, compared to age- and education-matched norms. Deficits should not be better accounted for by the person's premorbid intellectual level or native language, although this comparison might be best interpreted within a specialist clinical neuropsychological assessment. At both Level II and III studies, carefully-matched control groups will help inform detection of impairment. In addition, at both Level II and III studies, a neuropsychologist and a speech language pathologist are considered mandatory to assist with the administration and interpretation of the test results. Where individual assessment tools (rather than a screening or brief assessment battery) are used, the identification deficits on non-overlapping measures should be guided by the following considerations: measures of impairment should not be derived from the same test; and, tests on which impairment is identified should not involve a similar format (e.g. investigators would not include

impairment on two tests of attention-inhibition, or concept formation or two tests of naming, see Supplemental Table 2).

Although the above criteria will potentially exclude people who have a selective breakdown on only one executive function (other than verbal fluency) or language test, we are concerned not to over-diagnose ALSci.

Clinical assessments and research studies should rule out confounding factors that may or not may be associated with ALS. A comprehensive assessment should rule out other cognitive presentations. Assessment procedures should control for bulbar speech production impairments (dysarthria) and motor deficits wherever possible so that deficits are not primarily identified on the basis of timed tests. Where serial measurements are available, a decline from baseline of at least 1.5sd on a measure might also be considered to indicate (new) impairment, although caution also has to be taken to evaluate the likely effect of repeated testing on performance where no new deficits are elicited, especially where parallel versions of tests are not available. For this reason, control groups are vitally important in clinical trials and longitudinal research studies.

***ALS with behavioural impairment (ALSbi).*** While both the ECAS and ALS-CBS contain behavioural measures, the delineation of the behavioural characteristics can be further gained through either the Motor Neuron Disease Behaviour Scale (MiND-B) (110), the Amyotrophic Lateral Sclerosis-Frontotemporal Dementia-Questionnaire (ALSFTD-Q) (111) or the Frontal Behavioural Inventory – ALS Version (FBI-ALS) (44;112). In each, the diagnosis of ALSbi is dependent on evidence from informant interviews and clinical observation of alterations in behaviour that cannot be accounted for by disease-related limitations, psychological reaction to the ALS diagnosis, a premorbid personality disorder, the presence of a comorbid psychiatric disorder (e.g. anxiety or depression) or pseudobulbar affect.

MiND-B is a brief assessment (9 items) completed by a proxy informant who knows well the person diagnosed by ALS. It includes three domains: disinhibition, stereotypical behaviour and apathy. It is derived from the Cambridge Behavioural Inventory Revised, which was originally developed to be sensitive for FTD. The MiND-B was validated in ALS with a

data driven approach. Two cut-offs to distinguish ALS from ALS plus (defined in MiND-B as patients with either ALS<sub>Sci</sub> or ALS<sub>Bi</sub>) or FTD are available: 35/36: 90% sensitivity and 50% specificity and 33/36: 81% sensitivity and 75% specificity.

The ALSFTD- Q is a caregiver questionnaire that was developed to measure abnormal behaviour change in ALS and avoid response bias due to physical disability. The 25 items were selected on the basis of a systematic review of the ALS literature and cover apathy, irritability, disinhibition, emotional lability and altered food preference. It shows good construct validity against other measures of behaviour change (Frontal Systems Behaviour Scale and Frontal Behaviour Inventory) and discriminates well ALS-FTD from ALS and controls. The cut-offs for this scale provide distinctions between mild behavioural symptoms (ALS<sub>Bi</sub>) and more severe symptoms, although not for a particular behaviour.

Loss of insight must be established by comparing patients' and informants' accounts of behavioural change and this may require clinical opinion. One means of operationalizing insight is to analyze standardized score discrepancies between patient self-reports and caregiver reports of patient behavior. One study determined that ALS-FTD patients report significantly less behavioral change over time compared to their caregivers, and report fewer behavioral abnormalities overall (113). The extent of patient-caregiver discrepancy was not documented in ALS patients without dementia.

On the basis of information gained from a knowledgeable informant, a diagnosis of ALS<sub>Bi</sub> is defined by:

1. The identification of apathy with or without other behaviour change.

OR

2. The presence of two or more of the following behavioural symptoms: a) disinhibition, b) loss of sympathy and empathy, c) perseverative, stereotyped or compulsive behaviour, d) hyperorality/dietary change, e) loss of insight (see above), f) psychotic symptoms (e.g. somatic delusions, hallucinations, irrational beliefs). The behavioural features a-d, together with apathy, are drawn from current criteria for behavioural variant FTD (37).

The ECAS behaviour screen provides a checklist of symptoms from the diagnostic criteria which are marked as present or not. Other ALS-specific behavioural screens like the ALS-CBS and MiND-B provide published cut-off scores which are used to define ALSbi.

***ALS with combined cognitive and behavioural impairment (ALS-cbi).*** This new classification captures patients who fulfil criteria for both ALSci and ALSbi.

***ALS with frontotemporal dementia (ALS-FTD).*** A diagnosis of ALS-FTD is made when patients with ALS also show behavioural/cognitive changes in keeping with FTD.

A diagnosis of ALS-FTD is defined by:

1. Evidence of progressive deterioration of behaviour and/or cognition by observation or history

AND

2. The presence of at least 3 of the behavioural/cognitive symptoms outlined by Rascovsky et al (37).

OR

3. The presence of at least 2 of those behavioural/cognitive symptoms, together with loss of insight and/or psychotic symptoms

OR

4. The presence of language impairment meeting criteria for semantic dementia/semantic variant PPA or non-fluent variant PPA, as defined by Neary et al. (5) or Gorno-Tempini et al, (114). This may co-exist with behavioural/cognitive symptoms as outlined above.

***Neuroimaging studies in the diagnosis of a frontotemporal spectrum disorder in ALS.***

Neuroimaging continues to provide unique *in vivo* pathological insights into the expanding clinical and molecular syndrome of ALS (115). While frontotemporal cerebral



atrophy may be noted during CT or MRI performed as part of the routine clinical work-up of ALS patients, both are insensitive and in the clinical setting a subjective assessment must take into account normal age-related atrophy. SPECT, long-recognised to be capable of demonstrating reduced frontal uptake in cases of ALS associated with dementia (116), also lacks essential sensitivity for ALS cases with less marked cognitive or behavioural impairment. Automated assessment tools for detecting more subtle grey matter volume changes on high-resolution T1-weighted MRI (voxel-based morphometry), or frontotemporal white matter tract projections (diffusion tensor imaging), are not yet applicable to the individual patient. However, these more advanced structural MRI sequences continue to advance toward this ultimate aim (117), perhaps through combination with functional MRI connectivity measures (118).

More marked patterns of basal ganglia and cerebellar structural MRI change have been noted in ALS patients carrying pathological hexanucleotide expansions in *C9orf72* compared to apparently sporadic ALS cases (119;120). Furthermore, widespread structural MRI changes have been reported in studies involving pre-symptomatic *C9orf72* mutation carriers (121;122), offering the potential to study the evolution of broader cerebral pathology in ALS at a much earlier stage.

Positron emission tomography (PET) imaging continues to provide substantial knowledge regarding the anatomic and cellular topography of neuronal dysfunction in ALS, and increasingly, markers of non-neuronal involvement as critical mediators of the disease process. Advances in neuroimaging and the attendant increase in our understanding of the neural networks or connectome are beginning to provide greater clarity as to the nature of FTSD, and in particular the concept of FTSD as a disconnection syndrome with individual clinical phenotypes predicated on the nature of the neural network damage. Providing crisp clinical correlates to such neuroimaging advances underlies a significant proportion of the impetus to revising the criteria.

***Axis III. Additional non-motor disease manifestations.*** As with the 2009 Strong criteria (2), it is recommended that note be made of the presence or absence of non-motor manifestations, including extrapyramidal signs (bradykinesia, rigidity, tremor), cerebellar degeneration,

autonomic dysfunction, sensory impairment disproportionate to age or ocular movement abnormalities.

**Axis III recommendation.** Members of the Consensus Committee made no changes to this recommendation. As such, it is recommended that observations should be made of specific non-motor manifestations that are distinct from the neuropsychiatric and neuropsychological manifestations of frontotemporal dysfunction.

**Axis IV. Presence of disease modifiers.** In reviewing this recommendation, Members recognized that the majority of modifiers of the neuropsychological features of ALS would be captured within Axis I studies of the molecular genetics or within the specific tests of neuropsychology. All studies will contain the key variables of site of disease onset, gender and age. Hence, the view of the members of the consensus conference was that Axis IV was no longer required within the diagnostic algorithm of the frontotemporal spectrum disorders of ALS.

**Axis IV recommendation.** As noted above, members recommend that Axis IV is no longer required and be supplanted by information gained through the assessment of Axis I and II.

**Neuropathology recommendations.** The fundamental recommendations of the Strong criteria with respect to neuropathological diagnosis of ALS-FTSD remain unchanged. However, in keeping with the consideration of levels of complexity, it is recognized that not all cases will be examined as extensively as was proposed, although this remains the goal. As such, a complete neuropathological examination should be considered to be integral to the diagnosis, including examination of the brain and complete spinal cord given the high degree of regional variability of the disease and recent work suggesting a focal onset followed by spread (123-125). Spinal cord sections should continue to include cervical, thoracic and lumbar regions. Due to the pathognomonic involvement by p62 and dipeptide repeat (DPR) pathology in C9FTD/ALS, the

cerebellum must be included in the analysis (126;127). In all cases, the degree of involvement of both the UMN and LMN should be ascertained, and for the former, when not clearly evident on routine haematoxylin/eosin staining, identified using immunohistochemical evidence for a microglial neuroinflammatory response (e.g. HLA-DR3, CD68 or Iba1) and astrogliosis (GFAP), and special stain (e.g. Luxol-fast blue/Nissl) for secondary myelin loss. With the increasing recognition that neuronal cytoplasmic and nuclear inclusions within degenerating motor neurons in ALS can be composed of a broad range of cytoskeletal proteins and RNA binding proteins, often with multiple proteins depositing within the same degenerating motor neuron (128), there is now an extensive array of antibodies with which to confirm the presence of ALS. Most commonly however, immunostaining with antibodies directed towards protein ubiquitination (ubiquitin, p62), TDP-43 and FUS and demonstrating neuronal or glial inclusions would suffice for the diagnosis of LMN involvement in ALS. When full autopsy is possible, peripheral nerves and muscles should be part of the neuropathological work-up. Sampling frozen tissue for future biochemical and genetic analysis also is recommended.

The neuropathological correlate of FTD is frontotemporal lobar degeneration (FTLD). There are 3 major FTLD types depending on the hallmark pathological protein: FTLD-tau, FTLD-TDP and FTLD-FUS. A small minority of FTD cases are not expressing any of these proteins; those reacting with markers of the ubiquitin-proteasome system (UPS) represent FTLD-UPS whereas the rare, completely immunonegative cases fall into the group of FTLD-NOS (not otherwise specified). The large majority of cases of ALS with frontotemporal dysfunction belong to the FTLD-TDP type and exhibit TDP-43 immunoreactive inclusions within a range of neocortical and subcortical structures (the remaining cases are FTLD-FUS). They are predominantly in neurons in forms of neuronal cytoplasmic inclusions (NCIs), dystrophic neurites (DNs) and neuronal intranuclear inclusions (NIIs). The harmonized classification system for FTLD-TDP recognizes four subtypes (A, B, C and D) depending on the morphological forms and their frequency, characteristic neuroanatomical localization and presence or absence of other features like hippocampal sclerosis (129). There is good correlation with clinical phenotypes and genetic alterations (for example, the most frequent subtype A often present with bvFTD and FTD-ALS, with 50% of cases harboring *GRN* mutation or *c9orf72* expansion).

For neuropathological analysis, due to regional specificity, representative sections should include (among others) the anterior cingulate gyrus, precentral gyrus, superior frontal gyrus, superior temporal gyrus, amygdala, entorhinal cortex, hippocampus, basal ganglia and cerebellum. Immunostaining should include antibodies against TDP-43, FUS, p62, tau (e.g. AT8, pThr175) (130;131),  $\alpha$ -synuclein and in specific disease subtypes against neurofilament (in neuronal intermediate filament inclusion disease - NIFID), SOD-1, and various dipeptide repeats (DPRs) (in C9FTD/ALS) (132). Assessment of the presence of amyloid beta ( $A\beta$ ) pathology (e.g. amyloid plaques, cerebral amyloid angiopathy) with or without Alzheimer's disease type tau pathology also is mandatory. As discussed in the original Strong criteria, neuropathological studies should describe, by region, the extent of neuropathological changes, including the presence or absence of superficial linear spongiosis, the degree of neuronal loss, the presence or absence of hippocampal sclerosis (including subtle focal loss of CA1 neurons), and the nature of inclusions present (including dystrophic neurites, neuronal cytoplasmic inclusions, and neuronal intranuclear inclusions). The presence or absence of glial pathology, whether astrocytic or oligodendroglial, should be delineated. A stepwise approach is recommended for neuropathological work-up with special stains and immunohistochemistry of the relevant brain and spinal cord regions (132). A diagnostic algorithm has been proposed recently for neuropathological diagnosis of ALS, FTD and overlapping syndromes (132). More details about the principles and practice of neuropathological analysis and key morphological features are described in reference textbooks (132-134).

Since the publication of the original Strong criteria, the concept of staging of the frontotemporal degeneration of the neocortical and subcortical involvement in ALS has become increasingly of value in understanding the degree to which ALS-FTD may be a distinct entity from ALSci, ALS bi (and thus potentially ALScbi). Level III studies are thus recommended to include a full staging analysis as delineated by Halliday and colleagues (135).

### **Discussion.**

In contrast to the milieu in which the Strong criteria for the diagnosis of frontotemporal dysfunction were crafted, there is now a clearer appreciation of the significant proportion of ALS

patients who will have evidence of multidimensional dysfunction. When the Strong criteria were applied to ALS patients prospectively, more than 50% of ALS patients were found to have some form of frontotemporal disruptions or dementia, including probable Alzheimer's disease (39;136-139). There is, in fact, remarkable consistency across virtually all studies. The importance of recognizing these deficits lies in their impact on survival for a large proportion of ALS patients, an impact which is not yet integrated into the design of drug trials in ALS. And yet, executive dysfunction alone is a significant predictor of reduced survival from symptom onset (137). Behavioural dysfunction appears also to have an equal contribution to survival ( $p < 0.001$ ), seemingly in isolation from other variables (140). By increasing the rigor of defining the deficits in ALS, this should be clarified and ultimately, become a defined variable in the design and analysis of clinical trials in ALS.

Advances in our understanding of the spectrum of frontotemporal dysfunction that can occur in concert with the motor degeneration of ALS mandated a revision of the Strong criteria. Underpinning this is the realization that there exists a spectrum of deficits which have a degree of overlap, and hence the adoption of the term ALS frontotemporal spectrum disorders (ALS-FTSD). This is not meant to imply that the spectrum is a continuum, and indeed it is less clear that ALS-FTD is the natural endpoint of ALS<sub>Sci</sub>, ALS<sub>Bi</sub> or ALS<sub>(cbi)</sub>.

These revised criteria (Table 2) have addressed the issue of genetic testing more critically, in part driven by the explosion in knowledge of genetic mutations that are either causally associated with ALS, or identified as modifiers of the disease process. The discovery that many of these genetic mutations can be observed in ALS patients in whom there is no evidence for inheritance underscores the importance of using the term 'genetic' rather than 'familial ALS' to describe such cases. To that extent, we have proposed that all ALS can be stratified into those cases for which a genetic etiology is known, versus those for which one is not. Clearly, there remain cases for which the designation of familial is warranted based on a conventional analysis of the patient pedigree; we recommend that these cases also be subsumed under the terminology "genetic ALS". We are recommending further that all patients who are diagnosed as ALS-FTSD be offered the opportunity for genetic testing, and in the cases of research protocols, that this be mandatory. While ideally an individual should be tested for all genes identified as being causally linked (Table 1), this is impractical and beyond the resources

of many clinics or individuals. Genetic testing should, therefore, be modified according not only to the geography of origin of the patient, but to the nature of the deficit (for instance, a patient presenting with marked behavioural impairment, with or without psychosis, should first be tested for pathological hexanucleotide expansions of *C9orf72*).

Since the introduction of the Strong criteria, there also has been an increasing awareness that the neuropsychological deficits are pervasive across the spectrum of motor neuron diseases. The issue arises that even within the motor manifestations of ALS, it is increasingly recognized that there is considerable clinical phenotypic heterogeneity. This observation has driven controversy as to the degree to which defining this heterogeneity serves any clinical purpose, as opposed to considering all disorders of the motor neuron to simply be, on aggregate, a single disorder (i.e., lumping vs. splitting). Recent attempts at revising the diagnostic criteria for ALS have leaned towards the latter. However, in developing these revised Strong criteria, it is hoped that a clearer and more consistent set of criteria by which to define the specific variants of frontotemporal dysfunction will provide a clearer understanding of distinct pathophysiology of frontotemporal dysfunction in ALS, and potentially, selective treatment responses. While it remains unresolved whether clinically divergent presentations are due to disparate etiologies, it is prudent to maintain careful documentation of the clinical phenotype and encourage investigations that may link or associate specific presentations with unique biomarkers or etiologies. The absence of maintaining awareness of such clinically divergent motor neuron phenotypes, given our current understanding, raises the probability of obscuring a valuable treatment effect or a clinical association (perhaps with FTD spectrum) that could highlight a critical etiology. Hence, we have elected to maintain Axis I with a focus on defining the motor neuron disease succinctly.

Finally, as with the original Strong criteria, it is recognized that our understanding of the frontotemporal dysfunction which may occur in ALS will continue to evolve rapidly. Even now, the place of memory and language impairments in ALS are works in progress, as is defining the true breadth of behavioural and neuropsychiatric dysfunction which may occur. Moreover, recent investigations have begun to elucidate the influence of gender in ALS disease manifestation, including ALS*c* and ALS*b* (141). At this point in time however, it is our intention that these revised criteria will provide a greater level of diagnostic certainty.

### **Acknowledgments**

The consensus conference at which these criteria were formulated was generously supported by the ALS Society of Canada, the Michael Halls Endowment, and the Windsor-Essex County ALS Society. This paper also represents independent work part-funded (LHG) by the National Institute for Health Research (NIHR) Dementia Biomedical Research Unit at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

**Listing of conference attendees:** Michael Strong (conference organizer and chair), Sharon Abrahams, Thomas Bak, Emma Beeldman, Steve Bell, Michael Benatar, Mervin Blair, Robert Bowser, Emanuele Buratti, Danae Campos-Melos, Marvin Chum, Kristy Coleman, Chris Crockford, Karen Dunkerley, Marwa Elamin, Sali Farhan, Elizabeth Finger, Claire Flaherty, Tania Gendron, Laura Goldstein, Rosanne Govaarts, Francois Gros-Louis, Murray Grossman, Tibor Hortobagyi, Sarah Jesso, Kalyani Kansal, Yasumasa Kokubo, Suzee Lee, Julia MacKinley, Paula McLaughlin, Eneida Mioshi, Hiroshi Mitsumoto, Jennifer Murphy, Catherine Lomen-Hoerth, Lindsay Oliver, Chiadi Onyike, JB Orange, Markus Otto, Erik Pioro, Joost Raaphorst, Angela Roberts, Janice Robertson, Jonathon Rohrer, Jeffrey Rosenfeld, Vincenzo Silani, Julie Snowden, Carmela Tartaglia, Tamara Tavares, Christine Vande Velde, Kathryn Volkening, Susan Woolley

**Figure legends**

Figure 1. Schematic of levels of investigation. The revised criteria are designed to address the need for rapid, easily applied tools that can be used within the clinic (Level I) through to assessment tools that are more appropriate to research studies (Level III). Levels II and III require formal neuropsychological and speech and language expertise to implement, reflect higher statistical complexity, and include tests that may require further validation in the ALS population. Level II is an intermediary level which can be applied in clinical trials and would be appropriate to be included in clinical case reports as minimum datasets.



Supplemental Table 1. ALS susceptibility genes and their association with ALS, FTD or ALS-FTSD (sorted by chromosome)

Locus	Gene ID/Locus MIM number	Chromosome	Protein; functional changes	Inheritance	Clinical Phenotype				Reference
					FTD	ALS	ALS-FTSD	other	
	<i>CAMTA1</i>	1p36.31-p36.23	Calmodulin-binding transcription activator gene 1	sporadic	n/a	+	n/a	Cerebellar ataxia with mental retardation	(1)
	<i>KIFAP3</i>	1q24.2	Kinesin-associated protein 3; small G protein	sporadic	n/a	+ (3)	n/a		(2)
	<i>DCTN1</i>	2p13.1	Dynactin 1; axonal transport	AD	+ (9)	+	n/a	Perry syndrome	(3;4)
ALS17	<i>CHMP2B</i>	3p11.2	Charged multivesicular body protein 2B (also known as chromatin-modifying protein 2B); Vesicle trafficking	sporadic	+	+	n/a		(5;6)
	<i>NEK1</i>	4q33	Serine/threonine kinase NIMA (never in mitosis gene-A)-related kinase	sporadic		+			(7;8)
	<i>ARHGEF28</i>	5q13.2	Rho guanine nucleotide exchange factor 28	AD	n/a	+	n/a		(9-11)
	<i>SMN1</i>	5q13.2	Survival of motor neuron 1	AD, sporadic	n/a	+	n/a		(12;13)
	<i>MATR3</i>	5q31.2	Matrin 3; Nuclear matrix RNA/DNA binding protein	AD	+	+		Distal asymmetric myopathy	(14;15)
	<i>SQSTM1</i>	5q35.3	Sequestome 1; scaffold protein, NFkB	AD, sporadic	+	+	+	Paget's disease of	(16;17)

			signaling pathway					bone	
	<i>HFE</i>	6p22.1	Hemochromatosis; iron absorption	sporadic	n/a	+ (4)	n/a		(18;19)
ALS11	<i>FIG4</i>	6q21	Factor-Induced gene 4 (FIG4) homolog, SAC1 lipid phosphatase domain containing ( <i>Saccharomyces cerevisiae</i> ); polyphosphoinositide phosphatase	AD, sporadic	n/a	+ (8)	n/a	PLS, CMT	(20)
	<i>PON1</i>	7q21.3	Paraoxonase; organophosphate hydrolysis	sporadic	n/a	+	n/a		(21)
	<i>ELP3</i>	8p21.1	Elongator acetyltransferase complex subunit 3; transcript elongation	sporadic	n/a	+	n/a		(22)
ALS16	<i>SIGMAR1</i>	9q13.3	Sigma non-opioid intracellular receptor 1; Ion channel regulation	AR	+	+			(23;24)
	<i>ITPR2</i>	12p12.1-11.23	INOSITOL 1,4,5-triphosphate receptor type 2	sporadic	n/a	+ (1)	n/a		(25)
	<i>PRPH</i>	12q13.12	Peripherin; cytoskeleton	AD, sporadic	n/a	+ (6)	n/a		(26;27)
	<i>DAO</i>	12q24.11	D-amino-acid oxidase; Oxidative stress	AD		+			(28)
ALS13	<i>ATXN 2</i>	12q24.12	Ataxin 2; Oxidative stress	sporadic	n/a	+	n/a	SCA2	(29;30)
ALS9	<i>ANG</i>	14q11.2	Angiogenin, ribonuclease, RNase A family; DNA/RNA	AD, sporadic	n/a	+	+ (7)	PD	(31;32)

			processing						
	<i>TAF15</i>	17q12	TAF15 RNA polymerase II, TATA box binding protein (TDP)-associated factor, 68 kDa; DNA/RNA processing	AD	+	+ (5)	n/a		(33;34)
	<i>PGRN</i>	17q21.31	Progranulin; cell growth regulator	sporadic	+	+ (2)	n/a		(35)
	<i>UNC13A</i>	19p13.12	Unc-13 homologue A ( <i>Caenorhabditis elegans</i> ); Synaptic neurotransmitter release	sporadic	+	+	+		(36)
	<i>NEFH</i>	22q12.1-q13.1	Neurofilament, heavy polypeptide; cytoskeleton	sporadic	n/a	+	n/a		(37)
	<i>CHCHD10</i>	22q11.23	Coiled-coil-helix-coiled-coil-helix domain-containing protein 10; mitochondrial protein of the intermembrane space	AD	+	+ (11)			(38-42)

AD, autosomal dominant; ALS, amyotrophic lateral sclerosis; AR, autosomal recessive; CMT, Charcot-Marie-Tooth; FTD, frontotemporal dementia; NEK1, NIMA (never in mitosis gene) kinase 1; PD, Parkinson's disease; PMA, progressive muscular atrophy; SCA2, spinocerebellar atrophy 2

n/a – no literature reports of either the association or lack of association of specific gene mutations with either FTD or ALS-FTD

1. Note failure to replicate the association with ALS in a second study (43;44). This may imply a lack of association or a population-specific association.
2. Single case reports of ALS-FTD and limb onset ALS with PGRN missense mutation variants of uncertain biological significance
3. Initial report as a modifier of survival in ALS (2) have not been replicated (45;46)
4. Initial reports as being associated with ALS (18;19) have not been replicated (47;48)
5. Single variant identified in a mutational analysis (34); the bulk of the data relates specifically to neuropathological studies of the FET proteins in ALS.
6. Single mutation (27) or sequence variants in both fALS and sALS (26).
7. A single case report of ALS-FTD with a K171 *ANG* mutation (32).
8. Initial report as a susceptibility gene for ALS have not been replicated (49)
9. Single family in which ALS and FTD occur with a heterozygous R1101K mutation in the *DCTN1* gene (50)
10. A single family reported in which ALS and FTD occur; not replicated in French (51), Australian population studies (52) or Taiwanese (53) studies.
11. Note several population studies in which no pathogenic mutations have been observed amongst specific geographic populations, suggesting a degree of regional specificity (54;55)

Supplemental Table 2. Testing domains and testing paradigms recommended for the characterization of cognitive impairment in ALS.

Executive Domain		Test	Level I	Level II	Level III
Executive function					
	Screening	ALS-CBS (1)	X	X	X
	Screening & assessment	ECAS (2)	X	X	X
	Fluency	Verbal Fluency Index	X	X	X
	Concept formation	Wisconsin Card Sorting Test (3)		X	X
		Card Sort from the Delis Kaplan Executive Function System (4)		X	X
	Divided Attention	Trail Making Test (comparison between Trails B and A) (5)		X	X
	Attention-inhibition	Stroop Test (comparison between interference and control conditions) (6)		X	X
		Hayling Sentence Completion Test (7)		X	X
Social Cognition					
		Faux Pas (8)		X	X
		Reading Mind in the Eyes (9)		X	X
		Facial Emotional Expression (10)Test		X	X
		Judgement of Preference Test (11)			X
Language					
		Assessment of Pragmatic Abilities and Cognitive Substrates (APACS) (12)			X
		Picture description ([a] Picnic		X	X

		Scene Western Aphasia Battery; [b] 6-picture sequence (13)			
	Naming (pick one – select tests evaluate nouns + verbs)	Boston Naming Test – Second edition *Full (14) or short-forms (15)	X	X	X
		An Object and Action Naming Battery (16)			X
		Graded Naming Test (17)		X	X
		Expressive One-Word Picture Vocabulary Test – 4: Spanish-Bilingual Edition (co-normed with Receptive One-Word Vocabulary Test – 4/English and Spanish) (18)		X	X
		Expressive Vocabulary Test -2 (can be compared with PPVT IV scores) (19)		X	X
		Northwestern Naming Battery (nouns and verbs) (20)			X
		Test of Adolescent/Adult Word Finding (TAWF-2; nouns and verbs) (21)		X	X
	Naming - Verbs only	Action Naming Test <a href="http://www.bu.edu/lab/action-naming-test/">http://www.bu.edu/lab/action-naming-test/</a>			X
	Semantic/Concepts	Pyramids and Palm Trees (association task - objects) (22)		X	X
		Kissing and Dancing Test (association task – actions) (23)		X	X
	Single word comprehension	Peabody Picture Vocabulary Test IV (24)	X	X	X

		Receptive One-Word Picture Vocabulary Test – 4 (co-normed with Expressive One Word Vocabulary Test/English and Spanish) (18)		X	X
		Northwestern Naming Battery (25)			X
	Receptive Grammar	Test for Reception of Grammar – 2 (26)	X	X	X
		Northwestern Assessment of Verbs and Sentences (25)		X	X
	Syntax production	Northwestern Assessment of Verbs and Sentences* (English; Spanish and Chinese versions in progress) (25)		X	X
		Northwestern Anagram Test Non-verbal measure of syntax production (27)		X	X
	Pragmatic/Social Language	Pragmatic Protocol* (English) (28)			X
		Lille Communication Test (French) (29)			
		Assessment of Pragmatic Abilities and Cognitive Substrates (APACS) (12)			X
		Picture description ([a] Picnic Scene Western Aphasia Battery; [b] 6-picture sequences (13;30)		X	X
	Spoken Language	Topic Directed Interview (31)			X
		Assessment of Pragmatic Abilities and Cognitive Substrates (APACS) (12)			X
Memory					

	Comprehensive testing	<p>Pick one of:</p> <ul style="list-style-type: none"> <li>• Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (32),</li> <li>• Rey Auditory Verbal Learning test (33)</li> <li>• California Verbal Learning test-II,(34)</li> <li>• Wechsler Memory Scale-IV, (35)</li> <li>• Rivermead Behavioural Memory test (36)</li> </ul>		X	X
Behaviour					
	Screening	Edinburgh Cognitive and Behavioural ALS Screen (Behavioural Screen)	X	X	
		ALS-CBS (Behavioural Screen)	X	X	
		MiND-B		X	X
		ALSFTD-Q		X	X
		FBI-ALS (37;38)		X	X

Note that while this listing contains a selection of tests which have been previously shown to be sensitive to ALS, the list is far from exhaustive. As greater validation and experience in the use of domain-specific tests for the evaluation of FTSD occurs, it is expected that the testing paradigms recommended within each domain will be updated.



Supplemental Table 3. Characterization of ALSbi. Behaviour and neuropsychiatric domains (adapted from Rascovsky et al 2011 with the addition of psychosis and loss of insight) (1)

Domain	Symptom
Behavioural disinhibition	Socially inappropriate behaviour
	Loss of manners or decorum
	Impulsive, rash or careless actions
Apathy or inertia (which must be differentiated from depression)	Apathy
	Inertia
Loss of sympathy or empathy	Diminished responsiveness to others people's needs and feelings
	Diminished social interest, interrelatedness or personal warmth
Perseverative, stereotyped or compulsive/ritualistic behaviour	Simple repetitive movements
	Complex, compulsive or ritualistic behaviours
	Stereotypy of speech
Hyperorality and dietary changes	Altered food preferences
	Binge eating, increased consumption of alcohol or cigarettes
Psychosis	Delusions
	Hallucinations
Loss of insight	Denial of, or lack of awareness regarding deficits

Table 1: ALS- causative genes and their association with ALS, FTD or ALS-FTSD (adapted from (142;143))

Locus	Gene ID	Chromosome	Protein; functional changes	Inheritance	Clinical Phenotype				Reference
					FTD	ALS	ALS-FTSD	other	
ALS1	<i>SOD1</i>	21q22.11	Superoxide dismutase 1; Oxidative stress	AD, AR		+		PLS, PMA	(144)
ALS2	<i>ALS2</i>	2q33.2	ALSin/Rho guanine nucleotide exchange factors	AR		+		PLS, HSP	(145;146)
ALS4	<i>SETX</i>	9q34.13	Senataxin; DNA/RNA processing	AD		+		AOA2	(147)
ALS5	<i>SPG11</i>	15q21.1	Spatacsin; transmembrane protein	AR		+		HSP	(148;149)
ALS6	<i>FUS</i>	16p11.2	Fused in Sarcoma; RNA binding protein, DNA repair, exon splicing	AD	+	+	+		(150-152)
ALS7	<i>Unknown</i>	20p13	Unknown	AD		+			(153)
ALS8	<i>VAPB</i>	20q13.33	Vesicle-associated membrane protein-associated protein B and C; Altered axonal transport	AD		+		SMA	(154)
ALS10	<i>TARDBP</i>	1p36.22	TAR DNA binding protein (TDP-43); DNA/RNA processing	AD	+	+	+		(155-157)
ALS12	<i>OPTN</i>	10p13	Optineurin; membrane and vesicle trafficking, Protein degradation	AD, AR		+		+ (PDB)	(158)
ALS14	<i>VCP</i>	9q13.3	Valosin-containing protein; ATP-binding	AD	+	+	+	MSP	(159-161)

			protein, vesicle transport and fusion						
ALS15	<i>UBQLN2</i>	X11p.21	Ubiquilin 2; ubiquitination, protein degradation	X-linked	+	+	+		(162-164)
	<i>PFN1</i>	17p13.2	Profilin 1; actin binding protein, actin polymerization	AD	+	+			(165-167)
	<i>HnRNPA2 B1/A1</i>	7p15.2/12q13.3	Heterogeneous nuclear ribonucleoprotein; mRNA processing	AD		+		MSP	(168;169)
ALS-FTD1	<i>Unknown</i>	9q21-q22	Unknown	AD	+	+	+		(170)
ALS-FTD2	<i>C9orf72</i>	9p21.2	*Chromosome 9 open reading frame 72; unknown	AD	+	+	+		(171-178)
	<i>TBK1</i>	12q154.2	TANK-binding kinase 1; multifunctional kinase active in autophagosome-mediated degradation of ubiquitinated proteins; also role in inflammatory signaling	AD, sporadic	+	+			(179-184)

AD, autosomal dominant; ALS, amyotrophic lateral sclerosis; AOA2, ataxia-ocular apraxia 2; AR, autosomal recessive; FTD, frontotemporal dementia; HSP, hereditary spastic paraplegia; MSP, multisystem proteinopathy (previously referred to as IBMFTD or inclusion body myopathy with Paget's disease and frontotemporal dementia); PMA, progressive muscular atrophy; SMA, spinal muscular atrophy; TANK, TRAF family member-associated NF-kappa-B activator; TBK1, TANK-binding kinase 1

#### References

- (1) Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 2011;134:2456-77.

References For Supplemental Table 2

- (1) Woolley SC, York MK, Moore DH, Strutt AM, Murphy J, Schulz PE, et al. Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS). *Amyotroph Lateral Scler* 2010;11:303-11.
- (2) Abrahams S, Leigh PN, Harvey A, Vythelingum GN, Grise D, Goldstein LH. Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS). *Neuropsychologia* 2000;38:734-47.
- (3) Grant DA, Berg ED. *Wisconsin Card Sorting Test*. Odessa: Psychological Assessment Resources, 1990.
- (4) Delis DC, Kaplan E, Kramer JH. *Delis-Kaplan executive function system technical manual*. San Antonio, TX: The Psychological Corporation, 2001.
- (5) Reitan RM, Wolfson D. A selective and critical review of neuropsychological deficits and the frontal lobes. *Neuropsychology Review* 1994;4:161-98.
- (6) Golden C. *Stroop Color and Word Test*. Oxford: Hogrefe, 20002.
- (7) Burgess PW, Shallice T. *The Hayling and Brixton Tests*. London: Harcourt Press, 1997.
- (8) Stone VE, Baron-Cohen S, Knight RT. Frontal lobe contributions to theory of mind. *Journal of Cognitive Neuroscience* 1998;10:640-56.
- (9) Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I. The "Reading in the Mind in the Eyes" Test Revised Version: A study with normal adults, and adults with Asperger Syndrome or high-functioning autism. *Journal of Child Psychology and Psychiatry and Allied Disciplines* 2001;42:241-51.
- (10) Young A, Perret D, Calder A, Sprengelmeyer R, Ekman P. *Facial expression of emotion: Stimuli and Test*. Bury St Edmonds, England: Thames Valley Test Company, 2002.
- (11) Girardi A, Macpherson SE, Abrahams S. Deficits in emotional and social cognition in amyotrophic lateral sclerosis. *Neuropsychology* 2011;25:53-65.

- (12) Arcara G, Bambini V. A Test for the Assessment of Pragmatic Abilities and Cognitive Substrates (APACS): Normative Data and Psychometric Properties. *Front Psychol* 2016;7:70.
- (13) Nicholas LE, Brookshire RH. A system for quantifying the informativeness and efficiency of the connected speech of adults with aphasia. *J Speech Hear Res* 1993;36:338-50.
- (14) Kaplan E, Goodglass H, Weintraub S. Boston naming test. 2nd ed. Austin: PRO-ED, 2000.
- (15) Graves RE, Bezeau SC, Fogarty J, Blair R. Boston naming test short forms: a comparison of previous forms with new item response theory based forms. *J Clin Exp Neuropsychol* 2004;26:891-902.
- (16) Druks J, Masterson J. An object and action naming battery. London: Psychology Press, 2000.
- (17) McKenna P, Warrington EK. The Graded Naming Test. Windsor: NFER-Nelson, 1983.
- (18) Martin NA, Brownell R. Expressive one-word picture vocabulary: Spanish-bilingual edition. 4th ed. Novato: Academic Therapy Publications, 2011.
- (19) Williams KT. Expressive vocabulary test. 2nd ed. San Antonio: Pearson, 2007.
- (20) Thompson CK, Weintraub S. Northwestern Naming Battery. Evanston: Northwestern University, 2014.
- (21) German D. Test of adolescent/adult word finding. 2nd ed. Boston: VA Medical Centre, 2014.
- (22) Howard D, Patterson K. Pyramid and Palm Trees. Bury St Edmunds, Suffolk: Thames Valley Test Company, 1992.
- (23) Bak TH, Hodges JR. Kissing and dancing - a test to distinguish the lexical and conceptual contributions to noun/verb and action/object dissociation. Preliminary results in patients with frontotemporal dementia. *Journal of Neurolinguistics* 2003;16:169-81.
- (24) Dunn LM, Dunn DM. Peabody picture vocabulary test. 4th ed. San Antonio: Pearson, 2007.
- (25) Thompson CK. Northwestern assessment of verbs and sentences. Evanston: Northwestern University, 2011.
- (26) Bishop D. Test for reception of grammar - version 2 (TROG-2). London, UK: Pearson Assessment, 2003.

- (27) Weintraub S, Mesulam MM, Wieneke C, Rademaker A, Rogalski EJ, Thompson CK. The northwestern anagram test: measuring sentence production in primary progressive aphasia. *Am J Alzheimers Dis Other Demen* 2009;24:408-16.
- (28) Prutting CA, Kirchner DM. A clinical appraisal of the pragmatic aspects of language. *J Speech Hear Disord* 1987;52:105-19.
- (29) Rousseaux M, Delacourt A, Wyrzykowski N, Lefeurvre M. *Test Lillois de Communication*. Ortho edition. Ibergues, 2016.
- (30) Kertesz A. *Western Aphasia Battery*. New York: Grune and Stratton, 1982.
- (31) Ripich DN, Terrell B. Patterns of discourse cohesion and coherence in Alzheimer's disease. *J Speech Hear Dis* 1988;53:8-15.
- (32) Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. *J Clin Exp Neuropsychol* 1998;20:310-9.
- (33) Schmidt M. *Rey Auditory Verbal Learning Test*. Los Angeles: Western Psychological Services, 1996.
- (34) Delis DC, Kramer JH, Kaplan E, Ober BA. *California Verbal Learning Test manual - adult version (second edition)*. New York: The Psychological Corporation, 2000.
- (35) Wechsler D. *Wechsler Memory Scale (WMS-IV): administration and scoring manual*. 4th ed. San Antonio: The Psychological Corporation, 2009.
- (36) Wilson B, Greenfield E, Clare L, Baddeley A, Cockburn J, Watson P, et al. *Rivermead Behavioural Memory Test - Third Edition (RBMT-3)*. London, UK: Pearson Assessment, 2008.
- (37) Murphy J, Ahmed F, Lomen-Hoerth C. The UCSF screening exam effectively screens cognitive and behavioral impairment in patients with ALS. *Amyotroph Lateral Scler Frontotemporal Degener* 2015;16:24-30.
- (38) Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, et al. Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. *Neurology* 2016;86:813-20.

## Reference List

- (1) Fogh I, Lin K, Tiloca C, Rooney J, Gellera C, Diekstra FP, et al. Association of a Locus in the CAMTA1 Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. *JAMA Neurol* 2016.
- (2) Landers JE, Melki J, Meininger V, Glass JD, Van den Berg LH, van Es MA, et al. Reduced expression of *kinesin-associated protein3* (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. *Proc Natl Acad Sci USA* 2009;106:9004-9.
- (3) Farrer MJ, Hulihan MM, Kachergus JM, Dachsel JC, Stoessl AJ, Grantier LL, et al. DCTN1 mutations in Perry syndrome. *Nat Genet* 2009;41:163-5.
- (4) Munch C, Sedlmeier R, Meyer T, Homberg V, Sperfeld AD, Kurt A, et al. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. *Neurology* 2004;63:724-6.
- (5) Cox LE, Ferraiuolo L, Goodall EF, Heath PR, Higginbottom A, Mortiboys H, et al. Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). *PLoS One* 2010;5:e9872.
- (6) Parkinson N, Ince PG, Smith MO, Highley R, Skibinski G, Andersen PM, et al. ALS phenotypes with mutations in CHMP2B (charges multivesicular body protein 2B). *Neurology* 2006;67:1074-7.
- (7) Kenna KP, van Doornaal PT, Dekker AM, Ticozzi N, Kenna BJ, Diekstra FP, et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. *Nat Genet* 2016.
- (8) Brenner D, Muller K, Wieland T, Weydt P, Bohm S, Lule D, et al. NEK1 mutations in familial amyotrophic lateral sclerosis. *Brain* 2016;139:e28.
- (9) Droppelmann CA, Wang J, Campos-Melo D, Keller B, Volkening K, Hegele RA, et al. Detection of a novel frameshift mutation and regions with homozygosity within ARHGEF28 gene in familial amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degener* 2013.



- (10) Ma Y, Tang L, Chen L, Zhang B, Deng P, Wang J, et al. ARHGEF28 gene exon 6/intron 6 junction mutations in Chinese amyotrophic lateral sclerosis cohort. *Amyotroph Lateral Scler Frontotemporal Degener* 2014;15:309-11.
- (11) Zhang M, Xi Z, Ghani M, Jia P, Pal M, Werynska K, et al. Genetic and epigenetic study of ALS-discordant identical twins with double mutations in SOD1 and ARHGEF28. *J Neurol Neurosurg Psychiatry* 2016.
- (12) Corcia P, Mayeux-Portas V, Khoris J, de Toffol B, Autret A, Muh JP, et al. Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. *Ann Neurol* 2002;51:243-6.
- (13) Wang XB, Cui NH, Gao JJ, Qiu XP, Zheng F. SMN1 duplications contribute to sporadic amyotrophic lateral sclerosis susceptibility: evidence from a meta-analysis. *J Neurol Sci* 2014;340:63-8.
- (14) Johnson JO, Piro EP, Boehringer A, Chia R, Feit H, Renton AE, et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. *Nat Neurosci* 2014;17:664-6.
- (15) Leblond CS, Gan-Or Z, Spiegelman D, Laurent SB, Szuto A, Hodgkinson A, et al. Replication study of MATR3 in familial and sporadic amyotrophic lateral sclerosis. *Neurobiol Aging* 2016;37:209-21.
- (16) Le B, I, Camuzat A, Guerreiro R, Bouya-Ahmed K, Bras J, Nicolas G, et al. SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. *JAMA Neurol* 2013;70:1403-10.
- (17) Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. *Arch Neurol* 2011;68:1440-6.
- (18) Wang XS, Lee S, Simmons Z, Boyer P, Scott K, Liu W, et al. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. *J Neurol Sci* 2004;227:27-33.
- (19) Goodall EF, Greenway MJ, van M, I, Carroll CB, Hardiman O, Morrison KE. Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. *Neurology* 2005;65:934-7.
- (20) Chow CY, Landers JE, Bergren SK, Sapp PC, Grant AE, Jones JM, et al. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. *Am J Hum Genet* 2009;84:85-8.
- (21) Saeed M, Siddique N, Hung WY, Usacheva E, Liu E, Sufit RL, et al. Paraoxonase cluster polymorphisms are associated with sporadic ALS. *Neurology* 2006;67:771-6.

- (22) Simpson CL, Lemmens R, Miskiewicz K, Broom WJ, Hansen VK, van Vught PW, et al. Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. *Hum Mol Genet* 2009;18:472-81.
- (23) Al-Saif A, Al-Mohanna F, Bohlega S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. *Ann Neurol* 2011;70:913-9.
- (24) Belzil VV, Daoud H, Camu W, Strong MJ, Dion PA, Rouleau GA. Genetic analysis of SIGMAR1 as a cause of familial ALS with dementia. *Eur J Hum Genet* 2013;21:237-9.
- (25) van Es MA, van Vught PW, Blauw HM, Franke L, Saris CG, Andersen PM, et al. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. *Lancet Neurol* 2007;6:869-77.
- (26) Gros-Louis F, Larivière RC, Gowing G, Laurent S, Camu W, Bouchard J-P, et al. A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. *J Biol Chem* 2004;in press.
- (27) Corrado L, Carlomagno Y, Falasco L, Mellone S, Godi M, Cova E, et al. A novel peripherin gene (PRPH) mutation identified in one sporadic amyotrophic lateral sclerosis patient. *Neurobiol Aging* 2011;32:552-6.
- (28) Mitchell J, Paul P, Chen HJ, Morris A, Payling M, Falchi M, et al. Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. *Proc Natl Acad Sci U S A* 2010;107:7556-61.
- (29) Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. *Nature* 2010;466:1069-75.
- (30) Borghero G, Pugliatti M, Marrosu F, Marrosu MG, Murru MR, Floris G, et al. ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. *Neurobiol Aging* 2015;36:2906-5.
- (31) Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C, et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. *Nat Genet* 2006;34:411-3.
- (32) van Es MA, Diekstra FP, Baas F, Bourque PR, Schelhaas HJ, Strengman E, et al. A case of ALS-FTD in a large FALS pedigree with a K171 ANG mutation. *Neurology* 2009;72:287-8.
- (33) Hand CK, Khoris J, Salachas F, Gros-Louis F, Simoes Lopes AA, Mayeux-Portas V, et al. A novel locus for familial amyotrophic lateral sclerosis on chromosome 18q. *Am J Hum Genet* 2002;70:251-6.

- (34) Ticozzi N, Vance C, Leclerc AL, Keagle P, Glass JD, McKenna-Yasek D, et al. Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis. *Am J Med Genet B Neuropsychiatr Genet* 2011;156B:285-90.
- (35) Schymick JC, Yang Y, Andersen PM, Vonsattel JP, Greenway M, Momeni P, et al. Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes. *J Neurol Neurosurg Psychiatr* 2007;78:754-6.
- (36) Shatunov A, Mok K, Newhouse S, Weale ME, Smith B, Vance C, et al. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. *Lancet Neurol* 2010;9:986-94.
- (37) Al-Chalabi A, Andersen PM, Nilsson D, Chioza B, Andersson JL, Russ C, et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. *Hum Mol Genet* 1999;8:157-64.
- (38) Bannwarth S, Ait-El-Mkadem S, Chaussonot A, Genin EC, Lacas-Gervais S, Fragaki K, et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. *Brain* 2014;137:2329-45.
- (39) Chaussonot A, Le B, I, Ait-El-Mkadem S, Camuzat A, De SA, Bannwarth S, et al. Screening of CHCHD10 in a French cohort confirms the involvement of this gene in frontotemporal dementia with amyotrophic lateral sclerosis patients. *Neurobiol Aging* 2014;35:2884.
- (40) Chio A, Mora G, Sabatelli M, Caponnetto C, Traynor BJ, Johnson JO, et al. CHCH10 mutations in an Italian cohort of familial and sporadic amyotrophic lateral sclerosis patients. *Neurobiol Aging* 2015;36:1767-6.
- (41) Dols-Icardo O, Nebot I, Gorostidi A, Ortega-Cubero S, Hernandez I, Rojas-Garcia R, et al. Analysis of the CHCHD10 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. *Brain* 2015;138:e400.
- (42) Zhou Q, Chen Y, Wei Q, Cao B, Wu Y, Zhao B, et al. Mutation Screening of the CHCHD10 Gene in Chinese Patients with Amyotrophic Lateral Sclerosis. *Mol Neurobiol* 2016.
- (43) Chio A, Schymick JC, Restagno G, Scholz SW, Lombardo F, Lai SL, et al. A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. *Hum Mol Genet* 2009;18:1524-32.
- (44) Fernandez-Santiago R, Sharma M, Berg D, Illig T, Anneser J, Meyer T, et al. No evidence of association of FLJ10986 and ITPR2 with ALS in a large German cohort. *Neurobiol Aging* 2011;32:551-4.

- (45) Traynor BJ, Nalls M, Lai SL, Gibbs RJ, Schymick JC, Arepalli S, et al. Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients. *Proc Natl Acad Sci U S A* 2010;107:12335-8.
- (46) van Doormaal PT, Ticozzi N, Gellera C, Ratti A, Taroni F, Chio A, et al. Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study. *Neurobiol Aging* 2014;35:2420-4.
- (47) Yen AA, Simpson EP, Henkel JS, Beers DR, Appel SH. HFE mutations are not strongly associated with sporadic ALS. *Neurology* 2004;62:1611-2.
- (48) Chio A, Mora G, Sabatelli M, Caponnetto C, Lunetta C, Traynor BJ, et al. HFE p.H63D polymorphism does not influence ALS phenotype and survival. *Neurobiol Aging* 2015;36:2906-11.
- (49) Verdiani S, Origone P, Geroldi A, Bandettini Di PM, Mantero V, Bellone E, et al. The FIG4 gene does not play a major role in causing ALS in Italian patients. *Amyotroph Lateral Scler Frontotemporal Degener* 2013;14:228-9.
- (50) Munch C, Rosenbohm A, Sperfeld AD, Uttner I, Reske S, Krause BJ, et al. Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD. *Ann Neurol* 2005;58:777-80.
- (51) Millecamps S, De SA, Teyssou E, Daniau M, Camuzat A, Albert M, et al. Genetic analysis of matrin 3 gene in French amyotrophic lateral sclerosis patients and frontotemporal lobar degeneration with amyotrophic lateral sclerosis patients. *Neurobiol Aging* 2014;35:2882-5.
- (52) Fifita JA, Williams KL, McCann EP, O'Brien A, Bauer DC, Nicholson GA, et al. Mutation analysis of MATR3 in Australian familial amyotrophic lateral sclerosis. *Neurobiol Aging* 2015;36:1602.
- (53) Lin KP, Tsai PC, Liao YC, Chen WT, Tsai CP, Soong BW, et al. Mutational analysis of MATR3 in Taiwanese patients with amyotrophic lateral sclerosis. *Neurobiol Aging* 2015;36:2005-4.
- (54) Teyssou E, Chartier L, Albert M, Bouscary A, Antoine JC, Camdessanche JP, et al. Genetic analysis of CHCHD10 in French familial amyotrophic lateral sclerosis patients. *Neurobiol Aging* 2016;42:218-3.
- (55) Wong CH, Topp S, Gkazi AS, Troakes C, Miller JW, de MM, et al. The CHCHD10 P34S variant is not associated with ALS in a UK cohort of familial and sporadic patients. *Neurobiol Aging* 2015;36:2908.

